111 related articles for article (PubMed ID: 30382950)
1. Stimulation of N-methyl-D-aspartate receptors by exogenous and endogenous ligands improves outcome of brain injury.
Biegon A; Liraz-Zaltsman S; Shohami E
Curr Opin Neurol; 2018 Dec; 31(6):687-692. PubMed ID: 30382950
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of Brain d-Serine Mediates Recovery of Cognitive Function after Traumatic Brain Injury.
Liraz-Zaltsman S; Slusher B; Atrakchi-Baranes D; Rosenblatt K; Friedman Levi Y; Kesner E; Silva AJ; Biegon A; Shohami E
J Neurotrauma; 2018 Jul; 35(14):1667-1680. PubMed ID: 29648983
[TBL] [Abstract][Full Text] [Related]
3. Novel approach to the role of NMDA receptors in traumatic brain injury.
Shohami E; Biegon A
CNS Neurol Disord Drug Targets; 2014; 13(4):567-73. PubMed ID: 24168367
[TBL] [Abstract][Full Text] [Related]
4. D-Cycloserine Restores Experience-Dependent Neuroplasticity after Traumatic Brain Injury in the Developing Rat Brain.
Sta Maria NS; Reger ML; Cai Y; Baquing MAT; Buen F; Ponnaluri A; Hovda DA; Harris NG; Giza CC
J Neurotrauma; 2017 Apr; 34(8):1692-1702. PubMed ID: 27931146
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings.
Levin R; Dor-Abarbanel AE; Edelman S; Durrant AR; Hashimoto K; Javitt DC; Heresco-Levy U
J Psychiatr Res; 2015 Feb; 61():188-95. PubMed ID: 25554623
[TBL] [Abstract][Full Text] [Related]
6. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.
Labrie V; Roder JC
Neurosci Biobehav Rev; 2010 Mar; 34(3):351-72. PubMed ID: 19695284
[TBL] [Abstract][Full Text] [Related]
7. Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.
Heresco-Levy U; Shoham S; Javitt DC
Mov Disord; 2013 Apr; 28(4):419-24. PubMed ID: 23427107
[TBL] [Abstract][Full Text] [Related]
8. Neuroinflammation-Induced Memory Deficits Are Amenable to Treatment with D-Cycloserine.
Liraz-Zaltsman S; Yaka R; Shabashov D; Shohami E; Biegon A
J Mol Neurosci; 2016 Sep; 60(1):46-62. PubMed ID: 27421842
[TBL] [Abstract][Full Text] [Related]
9. Glutamate as a therapeutic target in psychiatric disorders.
Javitt DC
Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
[TBL] [Abstract][Full Text] [Related]
10. N-methyl-D-aspartate receptor antagonists in improving cognitive deficits following traumatic brain injury: a systematic review.
Khormali M; Heidari S; Ahmadi S; Arab Bafrani M; Baigi V; Sharif-Alhoseini M
Brain Inj; 2022 Jul; 36(9):1071-1088. PubMed ID: 35997315
[TBL] [Abstract][Full Text] [Related]
11. N-methyl-D-aspartate receptor agonists modulate homocysteine-induced developmental abnormalities.
Rosenquist TH; Schneider AM; Monogham DT
FASEB J; 1999 Sep; 13(12):1523-31. PubMed ID: 10463943
[TBL] [Abstract][Full Text] [Related]
12. Glycine modulators in schizophrenia.
Javitt DC
Curr Opin Investig Drugs; 2002 Jul; 3(7):1067-72. PubMed ID: 12186269
[TBL] [Abstract][Full Text] [Related]
13. Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.
Sershen H; Hashim A; Dunlop DS; Suckow RF; Cooper TB; Javitt DC
Neurochem Res; 2016 Feb; 41(1-2):398-408. PubMed ID: 26857796
[TBL] [Abstract][Full Text] [Related]
14. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
[TBL] [Abstract][Full Text] [Related]
15. Deficit of NMDA receptor activation in CA1 hippocampal area of aged rats is rescued by D-cycloserine.
Billard JM; Rouaud E
Eur J Neurosci; 2007 Apr; 25(8):2260-8. PubMed ID: 17445224
[TBL] [Abstract][Full Text] [Related]
16. [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].
Nishikawa T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):201-6. PubMed ID: 21226316
[TBL] [Abstract][Full Text] [Related]
17. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.
Heresco-Levy U; Javitt DC; Gelfin Y; Gorelik E; Bar M; Blanaru M; Kremer I
J Affect Disord; 2006 Jul; 93(1-3):239-43. PubMed ID: 16677714
[TBL] [Abstract][Full Text] [Related]
18. Identification of AICP as a GluN2C-Selective
Jessen M; Frederiksen K; Yi F; Clausen RP; Hansen KB; Bräuner-Osborne H; Kilburn P; Damholt A
Mol Pharmacol; 2017 Aug; 92(2):151-161. PubMed ID: 28588066
[No Abstract] [Full Text] [Related]
19. D-cycloserine prevents relational memory deficits and suppression of long-term potentiation induced by scopolamine in the hippocampus.
Portero-Tresserra M; Del Olmo N; Martí-Nicolovius M; Guillazo-Blanch G; Vale-Martínez A
Eur Neuropsychopharmacol; 2014 Nov; 24(11):1798-807. PubMed ID: 25453488
[TBL] [Abstract][Full Text] [Related]
20. Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute d-cycloserine.
Forsyth JK; Bachman P; Mathalon DH; Roach BJ; Ye E; Asarnow RF
Schizophr Bull; 2017 Sep; 43(5):1123-1133. PubMed ID: 28338977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
